The Isomerase PIN1 Controls Numerous Cancer-driving Pathways and is a Unique Drug Target

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2016 Jun 4

PMID 27256007

Citations 135

Authors

Xiao Zhen Zhou

Kun Ping Lu

Affiliations

Soon will be listed here.

Abstract

Targeted drugs have changed cancer treatment but are often ineffective in the long term against solid tumours, largely because of the activation of heterogeneous oncogenic pathways. A central common signalling mechanism in many of these pathways is proline-directed phosphorylation, which is regulated by many kinases and phosphatases. The structure and function of these phosphorylated proteins are further controlled by a single proline isomerase: PIN1. PIN1 is overactivated in cancers and it promotes cancer and cancer stem cells by disrupting the balance of oncogenes and tumour suppressors. This Review discusses the roles of PIN1 in cancer and the potential of PIN1 inhibitors to restore this balance.

Citing Articles

Discovery of Novel Pyrimidine Derivatives as Human Pin1 Covalent Inhibitors.

Tian M, Wang X, Tang G, Cui G, Zhou J, Jin J ACS Med Chem Lett. 2025; 16(1):101-108.

PMID: 39811131 PMC: 11726365. DOI: 10.1021/acsmedchemlett.4c00477.

PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway.

Wang X, Lee D, Xu H, Sui Y, Meisenhelder J, Hunter T Cancer Discov. 2025; 15(3):633-655.

PMID: 39808064 PMC: 11875963. DOI: 10.1158/2159-8290.CD-24-0866.

The mechanisms of Pin1 as targets for cancer therapy.

Liu C, Dan L, Li Q, Bajinka O, Yuan X Front Immunol. 2024; 15:1482088.

PMID: 39624096 PMC: 11609185. DOI: 10.3389/fimmu.2024.1482088.

Targeted degradation of Pin1 by protein-destabilizing compounds.

Alboreggia G, Udompholkul P, Rodriguez I, Blaha G, Pellecchia M Proc Natl Acad Sci U S A. 2024; 121(47):e2403330121.

PMID: 39531501 PMC: 11588135. DOI: 10.1073/pnas.2403330121.

Untangling the role of tau in sex hormone responsive cancers: lessons learnt from Alzheimer's disease.

Barker R, Chambers A, Kehoe P, Rowe E, Perks C Clin Sci (Lond). 2024; 138(21):1357-1369.

PMID: 39469929 PMC: 11522895. DOI: 10.1042/CS20230317.

References

Shimono Y, Zabala M, Cho R, Lobo N, Dalerba P, Qian D . Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009; 138(3):592-603. PMC: 2731699. DOI: 10.1016/j.cell.2009.07.011. View

Lu P, Wulf G, Zhou X, Davies P, Lu K . The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature. 1999; 399(6738):784-8. DOI: 10.1038/21650. View

Wulf G, Ryo A, Wulf G, Lee S, Niu T, Petkova V . Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J. 2001; 20(13):3459-72. PMC: 125530. DOI: 10.1093/emboj/20.13.3459. View

Ayala G, Wang D, Wulf G, Frolov A, Li R, Sowadski J . The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res. 2003; 63(19):6244-51. View

Khanal P, Namgoong G, Kang B, Woo E, Choi H . The prolyl isomerase Pin1 enhances HER-2 expression and cellular transformation via its interaction with mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1. Mol Cancer Ther. 2010; 9(3):606-16. DOI: 10.1158/1535-7163.MCT-09-0560. View

Maclachlan T, Somasundaram K, Sgagias M, Shifman Y, Muschel R, Cowan K . BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J Biol Chem. 2000; 275(4):2777-85. DOI: 10.1074/jbc.275.4.2777. View

Fujimori F, Takahashi K, Uchida C, Uchida T . Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G(0) arrest. Biochem Biophys Res Commun. 1999; 265(3):658-63. DOI: 10.1006/bbrc.1999.1736. View

Navin N . Cancer genomics: one cell at a time. Genome Biol. 2014; 15(8):452. PMC: 4281948. DOI: 10.1186/s13059-014-0452-9. View

Wulf G, Finn G, Suizu F, Lu K . Phosphorylation-specific prolyl isomerization: is there an underlying theme?. Nat Cell Biol. 2005; 7(5):435-41. DOI: 10.1038/ncb0505-435. View

10.

Nishi M, Sakai Y, Akutsu H, Nagashima Y, Quinn G, Masui S . Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors. Oncogene. 2013; 33(5):643-52. PMC: 4697746. DOI: 10.1038/onc.2012.614. View

11.

Connolly R, Nguyen N, Sukumar S . Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin Cancer Res. 2013; 19(7):1651-9. PMC: 3618522. DOI: 10.1158/1078-0432.CCR-12-3175. View

12.

Hilton B, Li Z, Musich P, Wang H, Cartwright B, Serrano M . ATR Plays a Direct Antiapoptotic Role at Mitochondria, which Is Regulated by Prolyl Isomerase Pin1. Mol Cell. 2015; 60(1):35-46. PMC: 4592481. DOI: 10.1016/j.molcel.2015.08.008. View

13.

Han X, Yoon S, Ding Y, Choi T, Choi W, Kim Y . Cyclosporin A and sanglifehrin A enhance chemotherapeutic effect of cisplatin in C6 glioma cells. Oncol Rep. 2010; 23(4):1053-62. DOI: 10.3892/or_00000732. View

14.

Ramelot T, Nicholson L . Phosphorylation-induced structural changes in the amyloid precursor protein cytoplasmic tail detected by NMR. J Mol Biol. 2001; 307(3):871-84. DOI: 10.1006/jmbi.2001.4535. View

15.

Wulf G, Liou Y, Ryo A, Lee S, Lu K . Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J Biol Chem. 2002; 277(50):47976-9. DOI: 10.1074/jbc.C200538200. View

16.

Eckerdt F, Yuan J, Strebhardt K . Polo-like kinases and oncogenesis. Oncogene. 2005; 24(2):267-76. DOI: 10.1038/sj.onc.1208273. View

17.

Lim J, Balastik M, Lee T, Nakamura K, Liou Y, Sun A . Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J Clin Invest. 2008; 118(5):1877-89. PMC: 2323189. DOI: 10.1172/JCI34308. View

18.

Lin Y, Lu L, Chen H, Duan X, Lin X, Feng X . SCP phosphatases suppress renal cell carcinoma by stabilizing PML and inhibiting mTOR/HIF signaling. Cancer Res. 2014; 74(23):6935-46. DOI: 10.1158/0008-5472.CAN-14-1330. View

19.

Nicole Tsang Y, Wu X, Lim J, Wee Ong C, Salto-Tellez M, Ito K . Prolyl isomerase Pin1 downregulates tumor suppressor RUNX3 in breast cancer. Oncogene. 2012; 32(12):1488-96. PMC: 3438320. DOI: 10.1038/onc.2012.178. View

20.

Ma S, Tang N, Tam C, Lui V, Lam L, Chiu H . A PIN1 polymorphism that prevents its suppression by AP4 associates with delayed onset of Alzheimer's disease. Neurobiol Aging. 2010; 33(4):804-13. PMC: 2988914. DOI: 10.1016/j.neurobiolaging.2010.05.018. View